Assessment of CYP2D6 re-activation after inhibitory effect of MDMA using tramadol as a probe

Shahin Nilchi; Davood Behdarvand; Hoda Lavasani; Mohammadreza Rouini; Yalda H. Ardakani

doi:10.1515/dmpt-2017-0037

Article

Assessment of CYP2D6 re-activation after inhibitory effect of MDMA using tramadol as a probe

, , , and

Published/Copyright: August 2, 2018

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Drug Metabolism and Personalized Therapy Volume 33 Issue 3

Abstract

Background

In recent years, the use of tramadol as a probe drug for human cytochrome p450 2D6 (CYP2D6) has been investigated. The objective of this study was to assess the recovery of rat CYP2D1 enzymatic activity after mechanism-based inhibition induced by a single dose of ecstasy (MDMA, 3,4-methylenedioxymethamphetamine) and evaluation of the tramadol ability as a probe drug. CYP2D1 is orthologous in rats to human CYP2D6 and was employed in the current study.

Methods

A total of 16 male rats were selected and divided into control and treatment groups. The control group did not receive MDMA, while rats in the treatment group received a single dose of MDMA (1 mg/kg) and were subsequently divided into groups that were tested at 1 h, 10 days or 30 days post-administration. The rats were subjected to liver perfusion with Krebs-Heinslet buffer containing tramadol for 60 min and the tramadol and M1 levels were determined by HPLC-fluorescence.

Results

The enzymatic activity of CYP2D1 for the 1-h group decreased significantly when compared with the control group (p<0.05). Moreover, enzymatic activity increased non-significantly in the 10- and 30-day groups in comparison with the control group. The concentration and AUC₀₋₆₀ of tramadol increased in the 1-h and 10-day groups when compared with the control group but decreased in the 30-day group; however, none of these changes was statistically significant (p>0.05). The M1 metabolic ratio in the 1-h group decreased significantly when compared with the control group (p<0.05). The M1 metabolic ratio of the 10-day group increased and of the 30-day group decreased, but neither of these changes were significant.

Conclusions

Regardless of the genotype, the enzymatic activity of rat CYP2D1 recovered by 10 days post-administration of MDMA. It appears that tramadol, irrespective of its stereoselectivity, is not able to appraise rat hepatic CYP2D1 activity. It can be extrapolated that tramadol is a not suitable probe drug for human hepatic CYP2D1 because CYP2D1 in rats is orthologous to human CYP2D6. Further animal and human studies are required to confirm this hypothesis.

Keywords: Ecstasy; human CYP2D6; isolated liver perfusion; MDMA; mechanism-based inhibition; probe drug; rat CYP2D1; rat orthologous gene; tramadol

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Clin Pharmacokinet 2009;48:761–804.10.2165/11318070-000000000-00000Search in Google Scholar

2. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23–37.10.1007/s00210-003-0832-2Search in Google Scholar

3. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149–56.10.1111/j.1365-2125.1996.tb00173.xSearch in Google Scholar

4. Freye E. Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs. Dordrecht: Springer, 2010.10.1007/978-90-481-2448-0Search in Google Scholar

5. Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Pharmacol Rev 2003;55:463–508.10.1124/pr.55.3.3Search in Google Scholar

6. UNODC. World Drug Report. Vienna, 2016.Search in Google Scholar

7. Christophersen AS. Amphetamine designer drugs – an overview and epidemiology. Toxicol Lett 2000;112–113:127–31.10.1016/S0378-4274(99)00205-2Search in Google Scholar

8. Shulgin AT. The background and chemistry of MDMA. J Psychoactive Drugs 1986;18:291–304.10.1080/02791072.1986.10472361Search in Google Scholar PubMed

9. Antolino-Lobo I, Meulenbelt J. Differential roles of phase I and phase II enzymes in 3, 4-methylendioxymethamphetamine-induced cytotoxicity. Drug Metab Dispos 2010;38:1105–12.10.1124/dmd.110.032359Search in Google Scholar PubMed

10. Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 2006;20:842–9.10.1177/0269881106065907Search in Google Scholar PubMed

11. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002;22:169–73.10.1097/00004714-200204000-00010Search in Google Scholar PubMed

12. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an “atypical” opioid analgesic. J Pharmacol Exp Ther 1992;260:275–85.10.1016/S0022-3565(25)11227-5Search in Google Scholar

13. Ardakani YH, Rouini M-R. Improved liquid chromatographic method for the simultaneous determination of tramadol and its three main metabolites in human plasma, urine and saliva. J Pharm Biomed Anal 2007;44:1168–73.10.1016/j.jpba.2007.04.012Search in Google Scholar

14. Lintz W, Erlaçin S, Frankus E, Urrag H. Biotransformation of tramadol in man and animal. Arzneimittelforschung 1981;31:1932–43.Search in Google Scholar

15. Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993;46:313–40.10.2165/00003495-199346020-00008Search in Google Scholar

16. Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall RR, Medve R, et al. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 2002;42:24–9.10.1177/0091270002042001002Search in Google Scholar

17. Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 2005;77:458–67.10.1016/j.clpt.2005.01.014Search in Google Scholar

18. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brøsen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005;77:312–23.10.1016/j.clpt.2004.11.002Search in Google Scholar

19. Liu H-C, Wang N, Yu Y, Hou Y-N. Stereoselectivity in trans-tramadol metabolism and trans-O-demethyltramadol formation in rat liver microsomes. Acta Pharmacol Sin 2003;24:85–90.Search in Google Scholar

20. Tomkins DM, Otton SV, Joharchi N, Berns T, Wu D, Corrigall WA, et al. Effect of CYP2D1 inhibition on the behavioural effects of d-amphetamine. Behav Pharmacol 1997;8:223–35.Search in Google Scholar

21. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2:875–94.10.1517/17425255.2.6.875Search in Google Scholar

22. Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall RR, Medve R, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Drug Metab Dispos 1997; 13:37–46.Search in Google Scholar

23. Störmer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000;28:1168–75.10.1016/S0026-895X(24)12045-7Search in Google Scholar

24. Rouini MR, Ardakani YH, Soltani F, Aboul-Enein HY, Foroumadi A. Development and validation of a rapid HPLC method for simultaneous determination of tramadol, and its two main metabolites in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 2006;830:207–11.10.1016/j.jchromb.2005.10.039Search in Google Scholar

25. Umehara K, Kudo S, Odomi M. Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes. Xenobiotica 1997;27:1121–9.10.1080/004982597239886Search in Google Scholar

26. Finnegan KT, Ricaurte GA, Ritchie LD, Irwin I, Peroutka SJ, Langston JW. Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res 1988; 447:141–4.10.1016/0006-8993(88)90974-2Search in Google Scholar

27. Kalant H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Can Med Assoc J 2001; 165:917–28.Search in Google Scholar

28. Green AR, Gabrielsson J, Marsden CA, Fone KC. MDMA: on the translation from rodent to human dosing. Psychopharmacology (Berl) 2009;204:375–8.10.1007/s00213-008-1453-8Search in Google Scholar PubMed

Received: 2017-11-21

Accepted: 2018-05-23

Published Online: 2018-08-02

Published in Print: 2018-09-25

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/dmpt-2017-0037

Keywords for this article

Ecstasy; human CYP2D6; isolated liver perfusion; MDMA; mechanism-based inhibition; probe drug; rat CYP2D1; rat orthologous gene; tramadol